FDA/CDC

Dexcom G6 gets FDA nod

Publish date: March 28, 2018

 


The Dexcom G6 integrated continuous glucose monitoring system just won FDA market clearance. Dexcom

Dexcom G6

“Along with this authorization, the FDA is establishing criteria, called special controls, which outline requirements for assuring iCGM devices’ accuracy, reliability and clinical relevance as well as describe the type of studies and data required to demonstrate acceptable iCGM performance. These special controls, when met along with general controls, provide reasonable assurance of safety and effectiveness for this device.”

The FDA evaluated data from two clinical studies of the Dexcom G6, which included 324 adults and children aged 2 years and older with diabetes. Both studies included multiple clinical visits within a 10-day period where system readings were compared to a laboratory test method that measures blood glucose values. No serious adverse events were reported during the studies.

Pages

Recommended Reading

Insulin pumps associated with lower risk of ketoacidosis and severe hypoglycemia in kids
MDedge Pediatrics
Pediatric psoriasis carries sharply increased risk of selected autoimmune comorbidities
MDedge Pediatrics
Herbal supplements offer value with cautions, caveats
MDedge Pediatrics
FDA approves first follow-on short-acting insulin product using abbreviated approval pathway
MDedge Pediatrics
Acne is linked to higher chances of major depression
MDedge Pediatrics
Arm-placement indication for CGM approved by FDA
MDedge Pediatrics
NIAID proposes 3-pronged plan for universal influenza vaccine
MDedge Pediatrics
Young diabetics are at sevenfold increased risk of sudden cardiac death
MDedge Pediatrics
MDedge Daily News: Have ‘The Talk’ about medical marijuana
MDedge Pediatrics
MDedge Daily News: Treating H. pylori slashed new gastric cancers
MDedge Pediatrics